WRF
KERX

Waddell & Reed Financial’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Waddell & Reed Financial’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-175,000
Closed -$2.98M – 575
2014
Q1 		$2.98M Buy
175,000
+75,000
+75% +$1.13M ﹤0.01% 523
2013
Q4 		$1.29M Buy
+100,000
New +$1.19M ﹤0.01% 551

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

Waddell & Reed Financial's KERX Position: Q2 2014 in Review

Waddell & Reed Financial sold out of Keryx Biopharmaceuticals Inc (KERX) in Q2 2014, closing a stake of 175,000 shares — an estimated $2.98M sold.

Waddell & Reed Financial first reported a position in KERX in Q4 2013 and held it in 2 quarters. The position peaked at $2.98M in Q1 2014. 135 funds tracked by Wall St. Rank hold KERX as of Q2 2014.

  • Waddell & Reed Financial reported no remaining Keryx Biopharmaceuticals Inc position as of Q2 2014 after selling out during the quarter.
  • Waddell & Reed Financial sold 175,000 Keryx Biopharmaceuticals Inc shares in Q2 2014, an estimated $2.98M.
  • Waddell & Reed Financial first reported a position in Keryx Biopharmaceuticals Inc in Q4 2013 and held it in 2 quarters.
  • Waddell & Reed Financial's Keryx Biopharmaceuticals Inc position peaked at $2.98M in Q1 2014.
  • 135 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q2 2014.

Based on Waddell & Reed Financial's 13F filing for Q2 2014, filed 14 Aug 2014.